ABISHEK ASOK

Pharm.D. candidate who is eager and committed and who has a strong love for medicine and pharmacy. Currently pursuing a Pharm.D. with an unwavering desire to succeed in clinical practice and pharmaceutical sciences.

• IPSCON CREATING NEXTGENPHARMACOLOGISTS
• NATIONAL BOARD OFEXAMINATION IN MEDICALSCIENCES
• IPSCON WORKSHOP
• VIKSHIT BHARAT @2047
• International webinar series lecture 2
• Live webinar on CORONA VIRUS & COVID 18

• Pharma expert Talk on 20th june 2020

· A detailed knowledge about medicines.

· Monitoring and analysis of prescription.

· Communication skills; Experienced with communicating and handling of patients during my internship.

· Assists in General Health Screening such as BP, Blood glucose monitoring.

· Good understanding of clinical trial process/phases and /or post marketing safety requirements.

· Presentation skills: Did case presentation during my course of study.

• ASSESSMENT OF RENOPROTECTIVE EFFECT OF CILINIDIPINE AND AMLODIPINE ALONG WITH TELMISARTAN IN PATIENTS WITH TYPE -2 DIABETES
• In conclusion, this prospective observational study contributes significant insights into the renoprotective effects and antihypertensive efficacy of Cilnidipine plus Telmisartan and Amlodipine plus Telmisartan combination therapies in patients with Type 2 Diabetes Mellitus (T2DM) and hypertension. Cilnidipine plus Telmisartan demonstrated superior renoprotective effects, as evidenced by significant improvements in renal parameters such as albuminuria, serum creatinine, and urinary albumin-to-creatinine ratio (UACR). In contrast, Amlodipine plus Telmisartan showed limited efficacy in providing renoprotection, particularly evident in the lack of significant improvements in key renal parameters. These findings have important clinical implications for the management of patients with T2DM and hypertension, suggesting that Cilnidipine plus Telmisartan combination therapy may offer superior cardiovascular and renal protection compared to Amlodipine plus Telmisartan. However, further research, including randomized controlled trials with larger sample sizes and longer follow-up durations, is warranted to validate these findings and elucidate the underlying mechanisms of action. Overall, the results of this study provide valuable evidence to guide treatment decisions and optimize outcomes in patients with T2DM and hypertension, ultimately improving their quality of life and reducing the burden of cardiovascular and renal complications.